R&D shuffle at AstraZeneca
This article was originally published in Scrip
AstraZeneca's R&D head Dr Martin Mackay has brought in his old Pfizer colleague Dr Briggs Morrison as executive vice-president of global medicines development, replacing Dr Anders Ekblom.
You may also be interested in...
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.